Lorbrena

Active Ingredient(s): Lorlatinib
FDA Approved: * November 2, 2018
Pharm Company: * PFIZER INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Lorbrena Overview

Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.[1] Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemistry 7 History 7.1 Clinical studies 7.2 Approval...

Read more Lorbrena Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lorlatinib

Recent Lorbrena Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lorlatinib
  • Tablet: 100mg, 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Lorbrena: (2 results)

Sorted by National Drug Code
  • 0069-0227 Lorbrena 25 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc
  • 0069-0231 Lorbrena 100 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc

Other drugs which contain Lorlatinib or a similar ingredient: (1 result)